Eurolimus™ – CLINICAL PROGRAM

Evidence for the safety and efficacy of the Eurolimus™ DES in CAD

Eurolimus™ in coronary aterial disease & acute coronary syndrom

1

Italian Registry

Eurolimus™ in a real-world registry with 2 years follow-up:

Retrospective, single center registry in Milan, Italy
171 patients with coronary aterial disease or acute coronary syndrom
Follow-up 25.6 ± 5.7 months

Main findings at 2 years follow-up:

Stent thrombosis 0%
Major adverse cardiac events 3.9%
Target lesion failure 0.9%

Greek Registry

Eurolimus™ in a real-world registry with 2 years follow-up:

Retrospective, single center registry in Thessaloniki, Greece
196 patients with coronary aterial disease or acute coronary syndrom
Follow-up 27.8 ± 5.2 months

Main findings at 2 years follow-up:

Stent thrombosis 0.5%
Major adverse cardiac events 8.4%
Target lesion failure 4.6%